Omg, ABBV is acting like they just won prom queen or something. So, their drug SKYRIZI® got this big thumbs-up from Canada’s drug people—again. Like, first it was Crohn’s, now ulcerative colitis. Boring names but whatever. Everyone’s all “yay, phase 3 trials” and “clinical evidence” but I’m like, did anyone ask if patients even care?
This feels like that annoying ex who keeps texting you like, “Look how great I am now,” but you know they just lucked out. ABBV is basically throwing a big party ‘cause they signed some letter of intent with the pan-Canadian Pharmaceutical Alliance. Sounds fancy, right? Nope. It’s just a bunch of suits saying, “Let’s maybe buy your drug.” Like, okay? Cool? I don’t know if anyone’s actually gonna use it or if investors are just pretending to care.
And omg, the way ABBV flexes with all these clinical trial names — MOTIVATE, ADVANCE, FORTIFY — it’s like a bad superhero movie lineup. Which one’s gonna really save the day? Guess we’ll see. But honestly, I’m just here waiting for the drama. ABBV acting all responsible and science-y is so not their vibe. Stocks are like exes—sometimes they’re doing the most, sometimes they ghost you. This one? Probably doing the most.
If you wanna see how ABBV’s like that one clingy ex who’s suddenly “better,” check out the energy drama and Netflix weirdness.
Think you’re wired for chaos? Tap here.